13F Portfolios

CAS Investment Partners, LLC — CARDLYTICS INC CDLX: Quarterly 13F Position History

CAS Investment Partners, LLC has reported CARDLYTICS INC (CDLX) on 28 13F-HR filings in Pactolio's tracked window, first appearing in Q2 2019. As of Q1 2026, the position is sized at 5,198,067 shares ($5.5M market value, 0.31% of the equity book).

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 28 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 5,198,067 0 $5.5M 0.31% $1.05
Q4 2025 5,198,067 0 $6.0M 0.26% $1.15
Q3 2025 5,198,067 415,855 -7.4% $12.6M 0.56% $2.43
Q2 2025 5,613,922 0 $9.2M 0.45% $1.65
Q1 2025 5,613,922 754,988 -11.9% $10.2M 0.66% $1.82
Q4 2024 6,368,910 50,823 -0.8% $23.6M 1.38% $3.71
Q3 2024 6,419,733 45,126 -0.7% $20.5M 1.36% $3.20
Q2 2024 6,464,859 +91,183 +1.4% $53.1M 4.15% $8.21
Q1 2024 6,373,676 +957,560 +17.7% $92.4M 8.28% $14.49
Q4 2023 5,416,116 0 $49.9M 6.03% $9.21
Q3 2023 5,416,116 0 $89.4M 11.46% $16.50
Q2 2023 5,416,116 0 $34.2M 5.21% $6.32
Q1 2023 5,416,116 0 $18.4M 3.77% $3.40
Q4 2022 5,416,116 0 $31.3M 7.48% $5.78
Q3 2022 5,416,116 0 $50.9M 9.29% $9.40
Q2 2022 5,416,116 0 $120.8M 18.32% $22.31
Q1 2022 5,416,116 +229,650 +4.4% $297.8M 19.93% $54.98
Q4 2021 5,186,466 +36,875 +0.7% $342.8M 17.89% $66.09
Q3 2021 5,149,591 +660,619 +14.7% $432.3M 20.60% $83.94
Q2 2021 4,488,972 0 $569.8M 24.24% $126.93
Q1 2021 4,488,972 0 $492.4M 25.16% $109.70
Q4 2020 4,488,972 +97,386 +2.2% $640.9M 35.51% $142.77
Q3 2020 4,391,586 +377,337 +9.4% $309.9M 21.48% $70.57
Q2 2020 4,014,249 +62,734 +1.6% $280.9M 30.25% $69.98
Q1 2020 3,951,515 +1,129,805 +40.0% $138.1M 30.38% $34.96
Q4 2019 2,821,710 +502,299 +21.7% $177.4M 29.17% $62.86
Q3 2019 2,319,411 +157,391 +7.3% $77.7M 17.17% $33.52
Q2 2019 2,162,020 $56.2M 14.39% $25.98

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did CAS Investment Partners, LLC first disclose a CDLX position in 13F-HR filings?

CAS Investment Partners, LLC first reported CARDLYTICS INC (CDLX) on its 13F-HR filing for the period ending 2019-06-30 (Q2 2019). The position has appeared on 28 reported quarters within Pactolio's tracked window.

What was CAS Investment Partners, LLC's most recent quarter-over-quarter share-count change in CDLX?

CAS Investment Partners, LLC held the same 5,198,067 shares of CDLX between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.

Does the implied price-per-share represent CAS Investment Partners, LLC's cost basis in CDLX?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.